Background-A polymer-free peripheral paclitaxel-eluting stent (PES, Zilver PTX, Cook, IN) has shown to improve vessel patency after superficial femoral angioplasty. A new-generation fluoropolymer-based PES (FP-PES; Eluvia, Boston Scientific, MA) displaying more controlled and sustained paclitaxel delivery promise to improve the clinical outcomes of first-generation PES. We sought to compare the biological effect of paclitaxel delivered by 2 different stent-coating technologies (fluoropolymer-based versus polymer-free) on neointimal proliferation and healing response in the familial hypercholesterolemic swine model of femoral restenosis. Methods and Results-The biological efficacy of clinically available FP-PES (n=12) and PES (n=12) Histological evaluation showed larger lumen areas and evidence of higher biological activity (smooth muscle cell loss and fibrin deposition) in the FP-PES compared with PES and bare metal stent. Conclusions-In the familial hypercholesterolemic swine model of femoral restenosis, the implantation of an FP-PES resulted in lower levels of neointimal proliferation and sustained biological effect ≤90 days compared with a polymerfree stent-based approach. (Circ Cardiovasc Interv. 2017;10:e004450.
L ocal drug delivery is rapidly emerging as the first line of therapy for the interventional treatment of superficial femoral artery (SFA) disease. [1] [2] [3] Paclitaxel-coated balloon (PCB) technologies have shown to be superior to plain balloon angioplasty in maintaining long-term vessel patency among patients undergoing SFA intervention. 1, 2 The pharmacokinetic behavior of PCB is highly variable and largely depends on the size and solubility of the paclitaxel particles delivered to the vessel surface. 4 It has been hypothesized that the variability in paclitaxel tissue levels displayed by PCB technologies may impact the durability of long-term clinical results. 2 In addition, a polymer-free paclitaxel-eluting stent (PES) technology has demonstrated to improve 5-year vessel SFA patency compared with an identical bare metal stent (BMS) control. 5 Similarly, despite the encouraging 12-month patency results, a progressive loss of lumen patency has also been reported and attributed to the highly variable pharmacokinetic profile resulting from the absence of a controlled mechanism of drug release. 6 New-generation peripheral polymer-based drugeluting stents promise to improve vessel patency and healing profile by providing a more sustainable and controllable environment after implantation. In this study, we compared the impact on neointimal proliferation and vascular healing of 2 clinically available peripheral PESs (polymer-free versus fluoropolymer-based) versus a BMS control in the familial hypercholesterolemic model of femoral restenosis.
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Device Description
Commercially available (in CE mark countries) fluoropolymer-based peripheral PES (FP-PES; Eluvia, Boston Scientific, Natick, MA) and polymer-free PES (PES; Zilver PTX, Cook Medical, Bloomington, IN) were compared against a BMS control (Innova, Boston Scientific, Natick, MA). The Eluvia stent uses a dual-layer system coating, which consists of primer n-butyl methacrylate layer, which promotes adhesion to the stent of an active layer comprising a combination of paclitaxel and polyvinylidene fluoride-hexafluoropropylene, enabling controlled release of the drug over time. This drug and polymer combination is intended to facilitate sustained release of the drug over the first 12 months after stent implantation. The Eluvia stent is based on the commercially available Innova stent platform, consisting of a self-expanding nitinol stent and an advanced, 6F low-profile triaxial delivery system for added support and placement accuracy. The stent architecture features a closed-cell design at each end of the stent for more predictable deployment and an opencell design along the stent body for improved flexibility, strength, and fracture resistance. The paclitaxel concentration is 0.167 μg/mm 2 stent surface area. The Zilver PTX drug-eluting stent is an open-cell design self-expanding nitinol stent with a polymer-free paclitaxel coating (3 μg/ mm 2 ). All devices used in this study were 6×40 mm.
Hypercholesterolemic Swine Model
A total of 18 familial hypercholesterolemic swines obtained from the University of Wisconsin, Department of Animal Sciences, were used in this study. The genotypic, clinical features and utility in the evaluation of local drug delivery devices in the SFA territory of this model have been already published. [7] [8] [9] [10] [11] Animals were maintained on a lowgrade cholesterol pig chow to increase the cholesterol levels and to accelerate the disease process. In this study, younger animals were used (≈8 months) because previous studies have demonstrated the accelerated progression of neointimal proliferation after vascular injury, despite the absence of significant atherosclerotic burden at this age. [9] [10] [11] The absence of significant atherosclerotic burden allows for consistent baseline vascular bed for implantation of test and control articles.
In-Stent Restenosis Model and Treatment
The Institutional Animal Care and Use Committee approved this study, and all animals received care in accordance with the Guide to Care and Use of Laboratory Animals (National Research Council, NIH Publication No. 85-23, 7 revised 1996). A week before the initial procedure, all animals were started on a low-grade, 0.6% cholesterol diet supplementation. Dual antiplatelet therapy consisting of clopidogrel (150 mg loading dose and 75 mg maintenance dose) and oral aspirin (325 mg loading dose and 150 mg maintenance dose) was initiated 1 day before procedure and maintained for the entire duration of the study. Seven days after diet supplementation (day 0), general anesthesia was induced with xylazine and telazol (tiletamine/zolazepam). After reaching an adequate anesthetic level, the animals were intubated and maintained with inhaled 1% to 3% isoflurane. Surgical access was obtained via the carotid artery with general sterile technique. Before catheterization, heparin (5000-10 000 U) was injected to maintain an activated clotting time >250 s. Nitroglycerin was administered intraarterially to prevent and relieve vasospasm. All SFAs were evaluated by intravascular ultrasound to select the treatment site. Vessel injury before stent implantation was induced by oversized balloon angioplasty (30% balloon to artery overstretch ratio) in both SFAs in each animal. A randomization matrix was developed before stent implantation. One SFA of each individual animal (n=18) was allocated to receive 1 of the 3 stent types in a randomized fashion. This was done in 6 blocks of 3
WHAT IS KNOWN
• Polymer-free paclitaxel-eluting stent has demonstrated improved 5-year vessel superficial femoral artery patency with paclitaxel-eluting stent when compared with bare metal stent in patients but has a short duration of drug delivery.
• Whether newer generation peripheral polymer-based drug-eluting stents may improve vessel patency because of more sustained drug delivery is not known.
WHAT THE STUDY ADDS
• In a hypercholestrolemic pig model, fluoropolymerbased paclitaxel-eluting stent enables controlled release of the drug over the first 12 months after stent implantation.
• Fluoropolymer-based paclitaxel-eluting stent resulted in higher levels of vessel patency, more uniform neointimal distribution, and sustained biological activity compared with a polymer-free control. Values are presented as median (interquartile range). BAR indicates balloon-to-artery ratio; BMS, bare metal stent; FP-PES, fluoropolymer-based paclitaxel-eluting stent; LA, lumen area; MLD, minimal lumen diameter; OCT, optical coherence tomography; PES, paclitaxel-eluting stent; QVA, quantitative vascular angiography; RA, reference area; RVD, reference vessel diameter; and SAR, stent-to-artery ratio. Fluoropolymer-Based Paclitaxel Delivery random permutations to assure that 6 animals received each type of stent. The contralateral unstented SFA was assigned to 1 of the other 2 stent types using 3 blocks of 2 random permutations to always assure that each animal would receive 2 different stent types. This resulted in properly balanced groups (FP-PES, n=12; PES, n=12; and BMS, n=12). All stents were implanted with a 20% stent to artery overstretch ratio. Angiography and optical coherence tomography (OCT) was performed post-treatment. On day 30 after implantation, all treated sites underwent interim angiographic and OCT imaging. Prior to scheduled termination at 90 days after implantation, final OCT and angiographic imaging was conducted in treated segments. Subsequently stented vessels were harvested for histological evaluation.
Quantitative Vascular Angiography
Quantitative vascular angiography analysis was performed using QAngio XA SoftwareTM 7.1.14.0 (Medis Medical Imaging System, Leiden, the Netherlands). The outer diameter of the contrast-filled catheter was used as the calibration standard, and the minimum lumen diameter was obtained from the single worst view, while the reference vessel diameter was automatically calculated by the interpolation method. The percent diameter stenosis was calculated from the minimum lumen diameter and the reference vessel diameter. Binary angiographic restenosis was defined as a >50% diameter stenosis at follow-up.
OCT Imaging
OCT images were recorded using the ILUMIEN PCI Optimization System (St Jude Medical, St Paul, MN). Motorized OCT pullbacks were performed at a rate of 20 mm/s. All images were acquired at 100 frames per second, displayed with a color look-up table and digitally archived. Qualitative analyses were performed with the commercial software (ILUMIEN OPTIS; St. Jude Medical, St. Paul, MN), and the following cross-sectional parameters were measured after calibration: the lumen area, the inner and outer scaffold area. Percentage area of stenosis was calculated as [1−(lumen area/inner scaffold area)]×100. Neointimal thickness (NIT) was measured as the distance from the inner surface of the scaffold struts to the luminal border. Values are presented as median (interquartile range). BAR indicates balloonto-artery ratio; BMS, bare metal stent; %DS, percentage of diameter stenosis; FP-PES, fluoropolymer-based paclitaxel-eluting stent; MLD, minimal lumen diameter; PES, paclitaxel-eluting stent; RVD, reference vessel diameter; and SAR, stent-to-artery ratio.
*P value for interaction with time. †P value for overall main effect. ‡If P<0.05 from control group within time point. 
Histological Analysis
An independent pathology laboratory (Alizee Pathology, LLC Thurmont, MD) conducted the histomorphometric analysis. The vessels were removed by standard surgical technique, rinsed in Lactated Ringer's solution to remove any remaining blood material, and then immersion-fixed in 10% neutral buffer formaline. Pressure fixation is not typically used in our studies because peripheral stented segments preserve their lumen after vessel harvesting. Each stented vessel was prepared for light microscopy and morphometric analysis. Treated vessels were cut at 5 in-stent levels and 2 reference vessel levels. All vessel segments were cut serially and stained with hematoxylin and eosin and elastin trichrome. The resulting slides were examined via light microscopy. The cross-sectional areas, including the external elastic lamina, the internal elastic lamina and lumen area of each section were measured. The NIT was measured and defined as the distance from the inner surface of the each strut to the luminal border. Neointimal area was defined as the difference of internal elastic lamina area minus lumen area. Percentage area of stenosis=[1−(lumen area/internal elastic lamina area)]×100. Qualitative histological assessment on healing was performed using standardized score system. 12 Peristrut inflammation was evaluated using a standardized inflammatory score for each individual strut. The grading is as follows: 0, no inflammatory cells surrounding the strut; 1, light, noncircumferential lymphohistocytic infiltrate surrounding the strut; 2, localized, moderate to dense cellular aggregate surrounding the strut noncircumferentially; and 3, circumferential dense lymphohistiocytic cell infiltration of the strut.
The average inflammatory score for each cross section was calculated by dividing the sum of inflammatory scores by the total number of struts at the examined section.
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Statistical Analysis
Statistical analysis was performed using SAS statistical software (version 9.4; SAS Institute Inc, NC) All data are presented as median with interquartile range. Baseline angiographic and OCT data together with terminal histology and NIT distribution were evaluated using mixed model analysis. The clustering of vessels within individual animals was modeled by including the animal as a random effect. Post hoc comparisons were performed using Scheffe's test. The dichotomous variable binary restenosis was compared between the 3 treatment groups at 90 days using a generalized linear mixed model that used a logit link function and also included a random effect for animal.
In choosing the analytic model for the follow-up angiographic and OCT data, several factors were considered. First, there is no nonparametric analog to 2-way mixed analysis of variance. Second, using the Kolmogorov-Smirnov test, most of the variables were found to not deviate significantly away from normality. Further, in those cases where a deviation away from normality was seen, the distributions did not demonstrate a high degree of skew. Third, and most importantly, parametric analysis of variance is particularly robust to violations of the normality assumption when the design is balanced, as is the case with these data. Therefore, the change in angiographic and OCT outcomes over 2 time periods (28 and 90 days) was compared between the 3 treatment groups (FP-PES, PES, and BMS) using 2 by 3 mixed analysis of variance. The clustering of vessels within individual animals was modeled by including the animal as a random effect. Post hoc comparisons were performed using Scheffe's test. The differences were consider significant only if calculated P value was <0.05.
Results
Quantitative Vascular Angiography
A summary of baseline angiographic data is presented in Table 1 . Before injury, the average vessel diameters were comparable among all groups. Also, the degree of balloon injury achieved in all groups was comparable (balloon-to-artery ratio: FP-PES, 1. 
OCT Imaging
A summary of postimplantation OCT data is presented in Table 1 . After device deployment, there were no differences in mean lumen or stent areas between all tested groups. OCT data at follow-up are summarized in Table 3 Figure 4 ).
Histological Analysis
The histological data are summarized in Table 4 . Representative imaging and histological sections of all 3 studied groups are shown in Figure 5 . Figure 6B ). 
Discussion
In this study, we compared the impact on neointimal proliferation and vascular healing of 2 clinically available peripheral PESs (polymer-free versus fluoropolymer-based) versus a BMS control in the familial hypercholesterolemic model of femoral restenosis. The major comparative findings in regards to the fluoropolymer-based delivery of paclitaxel are (1) significant difference in neointimal inhibition at 90 days tested in vivo by multimodality imaging and ex vivo by histology, (2) lower binary restenosis rates and absence of total occlusions when compared with controls; (3) histological evidence of ongoing biological activity compared with polymer-free PES ≤90 days. The animal model used in this study has been extensively validated in the evaluation of drug delivery technologies in the SFA territory. [9] [10] [11] In this model, the biological effect of paclitaxel delivery on restenosis prevention has been evaluated in the presence and absence of stents. [9] [10] [11] Periprocedural data indicate that all stents were deployed under the same interventional conditions, allowing comparison of all tested groups (Table 1) . Important technological differences exist between the PESs used in this study. The FP-PES stent uses an active layer comprising a combination of paclitaxel and polyvinylidene fluoride-hexafluoropropylene as a controlled delivery mechanism. The paclitaxel concentration is 0.167 μg/mm 2 of stent surface area. Conversely, the polymer-free PES is coated with paclitaxel in a polymer-free form at a concentration of 3.0 μg/mm 2 . The Eluvia system releases ≈40% of the drug within the first 30 days and continues to release drug, with an estimated 90% of the total drug eluted at 12 months. The polymer-free system conversely release 95% of the total paclitaxel within first 24 hours after deployment with sustained paclitaxel levels in the artery wall through 56 days.
14 Therefore, the FP-PES system not only releases a smaller burst dose compared with polymer-free PES but also produces a more sustained and controlled dose of paclitaxel overtime. However, in this study, although significant differences are reported ≤90 days after stent implantation, it is possible that because of the differences in drug release profile displayed by the devices tested, different healing responses might occur at later time points.
The results of this study confirm that controlled and sustained drug release is not only important to achieve higher levels of vessel patency but also produced a more homogenous pattern of neointimal formation and sustained inhibition of the proliferative response in the animal model. Multimodality imaging confirmed the superiority of the FP-PES in achieving higher levels of vessel patency. Quantitative vascular analysis revealed lack of total occlusions in the fluoropolymer stent group. Also, OCT analysis demonstrated that neointimal formation was not only lower but more homogeneously distributed in the FP-PES group compared with the PES group. The polymer used in the FP-PES group (poly-vinylidene fluoridehexafluoropropylene) is currently used in commercially available coronary everolimus-eluting stents (Xience V; Abbott, Santa Clara and Promus, Boston Scientific, Natick, MA) and has been shown to be highly biocompatible and display antithrombogenic properties. 15 Because of the chemical nature of the FP-PES coating and the fact the drug is released steadily without burst phenomenon, the effect on neointimal inhibition is more predictable and uniform. In contrast, polymer-free delivery results in heterogeneous and less organized pattern of neointimal inhibition. Finally, histological evaluation demonstrated that while in the PES group, there was little evidence of active biological activity at 90 days, in the FP-PES group, fibrin deposition and neointimal hypocellularity (smooth muscle cell loss) scores were higher, indicating an active antiproliferative effect. This finding is important because multiple clinical studies have shown that the restenotic process in peripheral vascular intervention peaks between 9 and 12 months, [16] [17] [18] and sustained therapeutic tissue levels of drug are needed to prevent restenosis in this critical period of the healing response.
Tissue pharmacokinetics modulates biological effect on restenosis and overall vessel patency. In the setting of PCB delivery, drug is passively retained on the surface of the vessel wall as a function of its particle size and solubility. 19 Paclitaxel transfer into the tissue is facilitated by concentration gradients and occurs in an uncontrolled fashion. Typically, arterial levels of paclitaxel rapidly decline 72 hours after balloon delivery and fall below therapeutic levels by 180 days. 20 First in-human clinical studies using different PCB technologies demonstrate that PCB decreases angiographic restenosis by 40% to 50% by 6 months after initial delivery compared with PTA. 21, 22 However, randomized controlled studies suggest that the effect on restenosis and vessel patency declines after the first 12 months. In the LEVANT 2 trial (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis 2), for example, primary patency at 12 months was 65% in the PCB group versus 52.6% in the PTA group (P=0.02), and TLR rates were comparable in both groups. 1 Some of the TLR events reported in PCB are focal and related to either excessive vascular recoil or dissections left behind occurring right after balloon dilatation. Then, paclitaxel-eluting metallic stents promise to improve the clinical outcomes shown by PCB. A first-generation polymer-free paclitaxel stent (Zilver PTX), used in this study, showed higher 1-year primary patency rates (84.4%) compared with standard of care intervention defined as PTA and provisional Zilver BMS implantation (67.4%). 5 Similar to what has been seen with PCT technologies, by 3 and 5 years, primary patency had declined to 71.5% and 66.4%, respectively. 5 Finally, early clinical evidence from the MAJESTIC study using the FP-PES used in this study suggests that sustained paclitaxel release achieved higher levels of patency rates (primary patency of 95%), with low rate of major adverse events (4%) driven by TLR events in 2 patients at 12-month follow-up. 23 High patency rates corresponded with favorable clinical outcomes. One month after FP-PES implantation, 96% of the patients had improved in Rutherford scale by ≥1 categories. These results were sustained through 1 year, with 81% exhibiting no symptoms (category 0) and 13% presenting with mild claudication (category 1).
Limitations
First, the experimental nature of the study may limit the translation of our findings to the human condition. Second, to standardize the injury model, relatively young animals with limited amount of atherosclerotic lesions are typically used. This approach decreases the potential for variability induced by the presence of significant disease but limits the ability to assess the device in the level of disease present in the target population. However, clinical data of randomized studies published to date seem to support our findings. Third, we used the 90-day followup time point for the evaluation of efficacy. It is possible that some of the differences seen in tissue levels among all devices could reflect important differences at later time points not evaluated in this study. Finally, the correlation of animal results to human clinical outcomes is still unclear in the peripheral vascular territory. However, because of the differences in drug release displayed by both DES tested in this study, we think the 90-day follow-up period describes an accurate picture of the biological response occurring at a critical time of drug release.
Conclusions
This study represents the first head-to-head comparison of 2 clinically available PESs used in SFA intervention today. In this experimental study, the FP-PES resulted in higher levels of vessel patency, more uniform neointimal distribution, and sustained biological activity compared with a polymer-free control. The durability of this biological effect and impact on vessel patency is currently under investigation in a randomized controlled trial.
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